Therefore, it remains to be determined if the expected elevations of GLP-1 and gastrin can be achieved in response to DPP-4i and PPI drugs, respectively, in most or all patients with T1D, and whether this might then be therapeutic. This evidence concerns the gene GLP1R and type 1 diabetes mellitus.